Fig. 1: Ad26/MVA + Env protein subunit boost therapeutic vaccine strategy with vesatolimod treatment. | npj Vaccines

Fig. 1: Ad26/MVA + Env protein subunit boost therapeutic vaccine strategy with vesatolimod treatment.

From: Therapeutic efficacy of an Ad26/MVA vaccine with SIV gp140 protein and vesatolimod in ART-suppressed rhesus macaques

Fig. 1

A Therapeutic vaccine study design. B–D Log transformed plasma SIVmac251 viral loads (gag copies/ml plasma) from onset of infection to week 72 post-infection. Limit of detection (LOD) for the SIV viral load qRT-PCR assay used in the study was >250 gag copies/ml plasma. Red lines denote median values across all time points.

Back to article page